Darius Mohammad Moshfeghi, MD
Ophthalmology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Moshfeghi’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A78163 · Current
Licensed to practise in California · since 2002 · expires 2028-03-31 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Virginia 0101277785Physician · since 2023 · expires 2028-03-31Told the state board they are board certified.Current ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
4 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Ophthalmologycertified 2024 · through 2030
Residency and fellowship
- Cole Eye Institute, Cleveland Clinic, Vitreoretinal SurgeryCLEVELAND, OHIO · 2002
- University of Tennessee Memphis, Ophthalmic Oncology & Orbital DiseasesMEMPHIS, TENNESSEE · 2000
- Tulane University School of Medicine, OphthalmologyNEW ORLEANS, LOUISIANA · 1999
- Tulane University School of Medicine, TransitionalNEW ORLEANS, LOUISIANA · 1996
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$82,136
Medicare paid this office $82,136 for 319 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of drug into eye | 66 | $40,398 | $84 |
| Return visit (30+ min) | 268 | $28,300 | $76 |
| Imaging of retina | 305 | $9,719 | $21 |
| Measurement of corneal curvature and depth of eye | 61 | $1,476 | $24 |
Who their Medicare patients are
319 Original Medicare patients in 2024. Average age 78 · Women 61% · Also on Medicaid 18% · Health risk score 1.27. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 70% · Diabetes 34% · Coronary heart disease 24% · Chronic kidney disease 20% · Cancer 19% · Atrial fibrillation 16% · Depression 15% · Heart failure 13% · COPD 9% · Stroke 8% · Dementia 7%.
The office billed $791,326, Medicare allowed $115,226 and paid $82,136; for 1,419 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 319 | 1,419 | 78 | 1.27 | $791,326 | $82,136 |
| 2023 | 297 | 1,201 | 78 | 1.33 | $621,696 | $78,565 |
| 2022 | 343 | 1,467 | 78 | 1.42 | $602,506 | $89,244 |
| 2021 | 403 | 1,677 | 77 | 1.38 | $677,571 | $101,982 |
| 2020 | 354 | 1,613 | 77 | 1.38 | $717,090 | $108,153 |
| 2019 | 424 | 1,927 | 76 | 1.42 | $875,635 | $131,396 |
| 2018 | 484 | 2,085 | 76 | 1.37 | $950,344 | $143,809 |
| 2017 | 533 | 2,296 | 76 | 1.35 | $914,838 | $147,669 |
| 2016 | 494 | 2,012 | 76 | 1.28 | $785,746 | $137,094 |
| 2015 | 488 | 2,326 | 76 | 1.27 | $1,184,597 | $268,897 |
| 2014 | 577 | 3,183 | 76 | 1.25 | $1,680,382 | $482,250 |
| 2013 | 582 | 3,166 | 76 | 1.29 | $1,640,954 | $428,646 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Injection of drug into eye | 63 | $42,975 | $88 |
| Return visit (30+ min) | 250 | $25,678 | $81 |
| Imaging of retina | 236 | $6,443 | $22 |
| Measurement of corneal curvature and depth of eye | 57 | $1,542 | $26 |
| Photography of the retina | 27 | $502 | $17 |
2022: 6 services
| Injection of drug into eye | 73 | $47,312 | $81 |
| Return visit (30+ min) | 300 | $29,732 | $78 |
| Imaging of retina | 310 | $8,426 | $22 |
| Measurement of corneal curvature and depth of eye | 54 | $1,482 | $27 |
| Established patient complete exam of visual system | 22 | $1,310 | $52 |
| Photography of the retina | 17 | $330 | $17 |
2021: 6 services
| Injection of drug into eye | 88 | $56,029 | $83 |
| Established patient complete exam of visual system | 246 | $18,863 | $61 |
| Return visit (30+ min) | 118 | $11,589 | $86 |
| Imaging of retina | 321 | $9,416 | $22 |
| New patient complete exam of visual system | 33 | $2,578 | $78 |
| Measurement of corneal curvature and depth of eye | 66 | $1,692 | $23 |
2020: 6 services
| Injection of drug into eye | 82 | $64,162 | $92 |
| Established patient complete exam of visual system | 303 | $25,492 | $63 |
| Imaging of retina | 296 | $8,413 | $21 |
| Measurement of corneal curvature and depth of eye | 60 | $1,583 | $24 |
| New patient complete exam of visual system | 16 | $1,135 | $71 |
| Injection of drug into eye | 11 | $1,067 | $97 |
2019: 5 services
| Injection of drug into eye | 92 | $73,271 | $90 |
| Established patient complete exam of visual system | 356 | $32,528 | $65 |
| Imaging of retina | 378 | $11,716 | $22 |
| Long return visit (40+ min) | 15 | $1,171 | $78 |
| New patient complete exam of visual system | 11 | $930 | $85 |
2018: 6 services
| Injection of drug into eye | 90 | $65,821 | $90 |
| Established patient complete exam of visual system | 408 | $37,523 | $63 |
| Imaging of retina | 440 | $14,178 | $22 |
| New patient complete exam of visual system | 21 | $1,648 | $78 |
| Long return visit (40+ min) | 15 | $1,146 | $76 |
| 2d ultrasound scan of eye tissue and structures | 12 | $589 | $35 |
2017: 9 services
| Injection of drug into eye | 109 | $65,007 | $90 |
| Established patient complete exam of visual system | 454 | $44,404 | $64 |
| Imaging of retina | 473 | $16,006 | $22 |
| New patient visit (45+ min) | 30 | $2,965 | $99 |
| New patient visit (60+ min) | 16 | $2,291 | $143 |
| Long return visit (40+ min) | 17 | $1,545 | $91 |
| New patient complete exam of visual system | 18 | $1,545 | $86 |
| Return visit (30+ min) | 18 | $1,411 | $67 |
| 2d ultrasound scan of eye tissue and structures | 13 | $555 | $40 |
2016: 11 services
| Injection of drug into eye | 106 | $50,832 | $88 |
| Established patient complete exam of visual system | 357 | $34,237 | $66 |
| Imaging of retina | 376 | $14,140 | $24 |
| Return visit (30+ min) | 84 | $4,990 | $55 |
| New patient visit (60+ min) | 22 | $2,812 | $128 |
| New patient visit (45+ min) | 21 | $2,036 | $97 |
| Long return visit (40+ min) | 22 | $1,798 | $82 |
| New patient complete exam of visual system | 19 | $1,296 | $68 |
| 2d ultrasound scan of eye tissue and structures | 22 | $1,242 | $46 |
| Examination of eye by ophthalmoscope with retinal drawing | 27 | $944 | $19 |
| Established patient problem focused exam of visual system | 11 | $778 | $49 |
2015: 16 services
| Injection, aflibercept, 1 mg | 18 | $93,160 | None |
| Injection of drug into eye | 100 | $42,565 | $87 |
| Established patient complete exam of visual system | 231 | $19,829 | $66 |
| Return visit (30+ min) | 199 | $17,052 | $65 |
| Imaging of retina | 346 | $15,607 | $25 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 13 | $14,908 | $1,065 |
| Injection of drug into eye | 20 | $7,959 | $98 |
| Established patient complete exam of visual system | 44 | $6,393 | $107 |
| Imaging of retina | 54 | $3,535 | $44 |
| Long return visit (40+ min) | 35 | $3,459 | $96 |
| Return visit (30+ min) | 32 | $2,792 | $87 |
| New patient visit (60+ min) | 15 | $2,134 | $142 |
| New patient visit (45+ min) | 17 | $1,479 | $87 |
| Short return visit (20+ min) | 23 | $1,318 | $44 |
| 2d ultrasound scan of eye tissue and structures | 20 | $1,047 | $46 |
| Photography of the retina | 16 | $446 | $22 |
2014: 21 services
| Injection, aflibercept, 1 mg | 23 | $165,169 | None |
| Injection, ranibizumab, 0.1 mg | 13 | $95,863 | None |
| Injection of drug into eye | 97 | $50,617 | $88 |
| Injection of drug into eye | 47 | $26,943 | $95 |
| Established patient complete exam of visual system | 245 | $19,002 | $64 |
| Imaging of retina | 365 | $13,096 | $25 |
| Return visit (30+ min) | 151 | $11,256 | $64 |
| Established patient complete exam of visual system | 61 | $9,044 | $110 |
| Imaging of retina | 88 | $6,200 | $42 |
| Return visit (30+ min) | 49 | $5,922 | $91 |
| Unclassified biologics | 20 | $4,779 | None |
| New patient visit (45+ min) | 38 | $3,887 | $102 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 32 | $2,921 | $44 |
| New patient visit (60+ min) | 13 | $1,944 | $150 |
| Long return visit (40+ min) | 17 | $1,776 | $99 |
| 2d ultrasound scan of eye tissue and structures | 27 | $1,758 | $49 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 14 | $1,519 | $108 |
| Short return visit (20+ min) | 29 | $1,501 | $41 |
| Short return visit (20+ min) | 17 | $1,126 | $51 |
| Examination of eye by ophthalmoscope with retinal drawing | 11 | $425 | $20 |
| Photography of the retina | 13 | $355 | $21 |
2013: 22 services
| Injection, aflibercept, 1 mg | 16 | $132,161 | None |
| Injection of drug into eye | 108 | $50,178 | $87 |
| Injection of drug into eye | 39 | $19,724 | $95 |
| Established patient complete exam of visual system | 187 | $16,039 | $65 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 11 | $15,736 | $1,311 |
| Return visit (30+ min) | 193 | $15,341 | $64 |
| Imaging of retina | 314 | $13,313 | $25 |
| Established patient complete exam of visual system | 51 | $8,006 | $114 |
| New patient visit (60+ min) | 47 | $6,389 | $136 |
| Return visit (30+ min) | 57 | $5,690 | $86 |
| Imaging of retina | 87 | $5,550 | $43 |
| Long return visit (40+ min) | 49 | $4,818 | $86 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 53 | $4,679 | $41 |
| Unclassified biologics | 16 | $3,624 | None |
| New patient visit (45+ min) | 31 | $3,231 | $104 |
| Long return visit (40+ min) | 22 | $2,811 | $128 |
| Examination of eye by ophthalmoscope with retinal drawing | 84 | $2,712 | $19 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 20 | $2,653 | $111 |
| 2d ultrasound scan of eye tissue and structures | 30 | $1,912 | $44 |
| Short return visit (20+ min) | 24 | $1,201 | $43 |
| Photography of the retina | 22 | $599 | $21 |
| Examination of eye by ophthalmoscope with retinal drawing | 16 | $411 | $26 |
Medicaid work
$36,550 in 2024
Medicaid paid $36,550 for 1,254 billed services this clinician did in 2024, up to 31 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 144 | $13,702 |
| Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral | 772 | $11,686 |
| Return visit (30+ min) | 110 | $6,124 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 129 | $2,157 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 70 | $1,893 |
| Service | 29 | $989 |
| 2024 | 1,254 | 6 | 31 | $36,550 |
| 2023 | 3,242 | 8 | 51 | $79,132 |
| 2022 | 2,779 | 8 | 44 | $90,069 |
| 2021 | 1,289 | 6 | 30 | $60,855 |
| 2020 | 1,417 | 6 | 42 | $44,209 |
| 2019 | 2,081 | 10 | 38 | $119,629 |
| 2018 | 2,037 | 11 | 46 | $101,802 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 257 | $21,915 |
| Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral | 2,145 | $21,639 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 165 | $14,326 |
| Return visit (30+ min) | 209 | $9,608 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 252 | $7,518 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 181 | $2,981 |
| Service | 18 | $614 |
| Short return visit (20+ min) | 15 | $531 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 283 | $33,209 |
| Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral | 1,895 | $22,673 |
| Aflibercept injection | 17 | $13,283 |
| Return visit (30+ min) | 227 | $9,579 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 63 | $4,798 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 197 | $3,963 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 82 | $2,087 |
| Service | 15 | $477 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 296 | $38,476 |
| Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral | 358 | $5,960 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 172 | $5,705 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 237 | $4,646 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 152 | $3,613 |
| Service | 74 | $2,455 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 304 | $19,167 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 557 | $10,791 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 198 | $5,709 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 170 | $4,758 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 158 | $2,812 |
| Service | 30 | $972 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 498 | $43,822 |
| Aflibercept injection | 56 | $30,631 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 532 | $10,892 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 290 | $7,721 |
| Service | 206 | $6,999 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent | 121 | $6,461 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 235 | $4,481 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 55 | $4,448 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial | 60 | $2,744 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 28 | $1,430 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 225 | $25,916 |
| Aflibercept injection | 47 | $21,682 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent | 288 | $12,764 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 427 | $11,436 |
| Service | 298 | $10,060 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 322 | $6,161 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 275 | $4,741 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial | 91 | $4,394 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 27 | $1,927 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $1,744 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 13 | $977 |
Drugs they prescribed that Part D paid
$649
Pharmacies billed $649 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 20) in 2024. Too few prescriptions to compare fairly with other clinicians.
20 generic and 0 brand-name prescriptions · $649 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Azelastine | 13 | $541 | $42 |
Year by year
| 2024 | 20 | None | 0% (0) | 0% | $649 |
| 2023 | 18 | None | 0% (0) | None | $1,051 |
| 2022 | 37 | 21 | 0% (0) | 30% | $3,606 |
| 2021 | 53 | 24 | 0% (0) | 25% | $2,869 |
| 2020 | 31 | None | 0% (0) | 39% | $1,185 |
| 2019 | 22 | 11 | 0% (0) | 59% | $1,418 |
| 2018 | 46 | 25 | 0% (0) | 46% | $2,943 |
| 2017 | 40 | 19 | 0% (0) | 53% | $3,826 |
| 2016 | 56 | 25 | 0% (0) | 84% | $6,772 |
| 2015 | 48 | 23 | 0% (0) | 85% | $5,361 |
| 2014 | 83 | 40 | 0% (0) | 65% | $6,771 |
| 2013 | 95 | 43 | 0% (0) | 66% | $7,646 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Azelastine | 14 | $398 | $28 |
2022: 1 drug
| Azelastine | 15 | $539 | $36 |
2021: 1 drug
| Azelastine | 22 | $1,528 | $69 |
2017: 1 drug
| Pataday | 11 | $1,857 | $169 |
2016: 1 drug
| Pataday | 28 | $4,535 | $162 |
2015: 2 drugs
| Pataday | 13 | $2,555 | $197 |
| Prednisolone Acetate | 16 | $827 | $52 |
2014: 3 drugs
| Pataday | 19 | $2,673 | $141 |
| Ketorolac Tromethamine | 12 | $334 | $28 |
| Latanoprost | 15 | $234 | $16 |
2013: 4 drugs
| Patanol | 11 | $1,926 | $175 |
| Latanoprost | 18 | $295 | $16 |
| Prednisolone Acetate | 12 | $290 | $24 |
| Ketorolac Tromethamine | 11 | $283 | $26 |
Money from drug and device companies
$372,743 in 2025
| 2025 | 5 | 32 | $348,000 | $372,743 |
| 2024 | 5 | 35 | $292,070 | $293,341 |
| 2023 | 5 | 14 | $146,674 | $147,032 |
| 2022 | 2 | 14 | $250,125 | $250,170 |
| 2021 | 2 | 9 | $118,375 | $119,126 |
| 2020 | 5 | 17 | $190,797 | $190,816 |
| 2019 | 4 | 11 | $41,932 | $75,959 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ocular Therapeutix | Dextenza | $372,531 | 28 payments
|
| Topcon Healthcare | None | $84 | 1 payment
|
| Alcon Vision | Unity | $45 | 1 payment
|
| Astellas Pharma US | Izervay | $42 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $41 | 1 payment
|
See all 32 published payments
| Ocular Therapeutix | Consulting · 2025-12-31 | None | $36,000 |
| Ocular Therapeutix | Meals · 2025-12-17 | Dextenza | $346 |
| Ocular Therapeutix | Consulting · 2025-11-30 | None | $36,000 |
| Ocular Therapeutix | Consulting · 2025-11-03 | None | $36,000 |
| Topcon Healthcare | Meals · 2025-10-18 | None | $84 |
| Ocular Therapeutix | Meals · 2025-10-18 | Dextenza | $25 |
| Apellis Pharmaceuticals | Meals · 2025-10-17 | Syfovre | $41 |
| Ocular Therapeutix | Meals · 2025-10-16 | Dextenza | $137 |
| Ocular Therapeutix | Meals · 2025-09-13 | Dextenza | $18 |
| Ocular Therapeutix | Meals · 2025-09-12 | Dextenza | $63 |
| Astellas Pharma US | Meals · 2025-09-11 | Izervay | $42 |
| Ocular Therapeutix | Meals · 2025-09-11 | Dextenza | $16 |
| Ocular Therapeutix | Meals · 2025-09-11 | Dextenza | $214 |
| Ocular Therapeutix | Consulting · 2025-09-02 | None | $36,000 |
| Alcon Vision | Meals · 2025-08-02 | Unity | $45 |
| Ocular Therapeutix | Consulting · 2025-08-01 | None | $36,000 |
| Ocular Therapeutix | Meals · 2025-07-30 | Dextenza | $269 |
| Ocular Therapeutix | Consulting · 2025-06-29 | None | $36,000 |
| Ocular Therapeutix | Meals · 2025-06-21 | Dextenza | $29 |
| Ocular Therapeutix | Consulting · 2025-05-31 | None | $36,000 |
| Ocular Therapeutix | Meals · 2025-05-09 | Dextenza | $107 |
| Ocular Therapeutix | Consulting · 2025-04-09 | None | $24,000 |
| Ocular Therapeutix | Consulting · 2025-03-12 | None | $24,000 |
| Ocular Therapeutix | Consulting · 2025-03-05 | None | $24,000 |
| Ocular Therapeutix | Travel · 2025-01-31 | None | $3,471 |
| Ocular Therapeutix | Travel · 2025-01-31 | None | $19,200 |
| Ocular Therapeutix | Consulting · 2025-01-31 | None | $24,000 |
| Ocular Therapeutix | Meals · 2025-01-17 | Dextenza | $67 |
| Ocular Therapeutix | Meals · 2025-01-17 | Dextenza | $76 |
| Ocular Therapeutix | Meals · 2025-01-17 | Dextenza | $155 |
| Ocular Therapeutix | Meals · 2025-01-16 | Dextenza | $277 |
| Ocular Therapeutix | Meals · 2025-01-15 | Dextenza | $60 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $293,341
| Ocular Therapeutix | Dextenza | $193,271 | 25 payments
|
| Alexion Pharmaceuticals | None | $90,000 | 5 payments
|
| Boehringer Ingelheim International GmbH | None | $4,250 | 2 payments
|
| Akebia Therapeutics | None | $3,000 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $2,820 | 2 payments
|
2023: $147,032
| Alexion Pharmaceuticals | None | $145,159 | 7 payments
|
| Genentech | None | $1,515 | 1 payment
|
| Alcon Vision | Constellation | $168 | 3 payments
|
| Regeneron Pharmaceuticals | Eylea | $110 | 2 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $81 | 1 payment
|
2022: $250,170
| Alexion Pharmaceuticals | None | $250,125 | 13 payments
|
| Apellis Pharmaceuticals | None | $45 | 1 payment
|
2021: $119,126
| Alexion Pharmaceuticals | None | $118,375 | 7 payments
|
| Alcon Vision | None | $751 | 2 payments
|
2020: $190,816
| Alexion Pharmaceuticals | None | $117,375 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Non-Covered | $37,855 | 4 payments
|
| Regeneron Pharmaceuticals | Eylea | $32,767 | 5 payments
|
| Alcon Vision | Constellation | $2,800 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $75,959
| Bayer HealthCare Pharmaceuticals | Non-Covered | $48,959 | 5 payments
|
| Regeneron Pharmaceuticals | Eylea | $26,857 | 4 payments
|
| Novartis Pharmaceuticals | Beovu | $77 | 1 payment
|
| Allergan | Ozurdex | $66 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharma AG · Crth258b2301 & Crth258b2302 · 2020 | This clinician | $106,882 |
| Apellis Pharmaceuticals, Inc. · Study To Compare the Efficacy and Safety of Intravitreal Apl-2 Therapy With Sham Injections in Patients With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration · 2022 | Their institution | $42,033 |
| Novartis Pharma AG · Crth258b2301, Crth258b2302, Crth258c2301, Crth258c2302, Crth258aus04 · 2020 | This clinician | $25,900 |
| Novartis Pharma AG · Crth258b2301, Crth258b2302, Crth258c2301, Crth258c2302, Crth258aus04 · 2020 | Their institution | $25,725 |
| Novartis Pharma AG · Crth258b2301 & Crth258b2302 · 2020 | Their institution | $18,544 |
| Novartis Pharma AG · Crth258a2301, Crth258a2302 · 2021 | This clinician | $11,550 |
| Regeneron Pharmaceuticals, Inc. · Randomized, Controlled, Multi-Center Study To Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared To Laser Photocoagulation in Patients With Retinopathy of Prematurity · 2019 | This clinician | $2,907 |
| Regeneron Pharmaceuticals, Inc. · Randomized, Controlled, Multi-Center Study To Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared To Laser Photocoagulation in Patients With Retinopathy of Prematurity · 2023 | This clinician | $1,828 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal Vegf Trap in Subjects With Neovascular Age-Related Macular Degeneration · 2019 | This clinician | $764 |
| F. Hoffmann-La Roche AG · Va2 Phiii · 2025 | This clinician | $281 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1386702819
- Licence
- CA A78163, VA 101277785California A78163: Current · expires 2028-03-31Virginia 0101277785: Current Active
- Trained
- Tulane University School of Medicine, 1995
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2452 Watson Ct Ste 2277, Palo Alto, CA, 94303
- NPI first listed
- 2006-12-05
- NPI last updated
- 2026-06-16
- NPI record certified
- 2026-06-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305